估算目标框架在临床药理学试验中的潜力：一些讨论要点。
The potential of the estimands framework for clinical pharmacology trials: Some discussion points.
机构信息
University of the Free State, Bloemfontein, South Africa.
medac GmbH, Wedel, Germany.
出版信息
Br J Clin Pharmacol. 2020 Jul;86(7):1240-1247. doi: 10.1111/bcp.14233. Epub 2020 Mar 3.
Abstract
The recently finalised and published guideline ICH E9 (R1) introduced a new framework for the statistical analysis of clinical trials, namely that of "estimands". While the framework was originally developed for the analysis of late-phase trials, it could also provide a rigorous basis for the analysis of clinical pharmacology trials. We illustrate potential applications on two examples: a multiple dose pharmacology trial and the interpretation of confirmatory bioequivalence (BE) trials according to the current FDA and EMA BE guidelines.
摘要
最近定稿并发布的 ICH E9（R1）指南为临床试验的统计分析引入了一个新框架，即“目标”。虽然该框架最初是为后期试验的分析而开发的，但它也可以为临床药理学试验的分析提供严格的基础。我们通过两个例子来说明潜在的应用：一个多剂量药理学试验和根据当前 FDA 和 EMA BE 指南解释确证生物等效性（BE）试验。
相似文献
1
The potential of the estimands framework for clinical pharmacology trials: Some discussion points.估算目标框架在临床药理学试验中的潜力：一些讨论要点。
Br J Clin Pharmacol. 2020 Jul;86(7):1240-1247. doi: 10.1111/bcp.14233. Epub 2020 Mar 3.
2
Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice.临床试验中的目标选择：实践 ICH E9(R1)。
Ther Innov Regul Sci. 2020 Mar;54(2):324-341. doi: 10.1007/s43441-019-00061-x. Epub 2020 Jan 4.
3
Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines.定义临床试验中的疗效评估指标：ICH E9(R1) 指南示例说明。
Ther Innov Regul Sci. 2020 Mar;54(2):370-384. doi: 10.1007/s43441-019-00065-7. Epub 2020 Jan 6.
4
The detailed clinical objectives approach to designing clinical trials and choosing estimands.详细临床目标法在临床试验设计和效应指标选择中的应用。
Pharm Stat. 2021 Nov;20(6):1112-1124. doi: 10.1002/pst.2129. Epub 2021 May 20.
5
Incorporating estimands into clinical trial statistical analysis plans.将估计量纳入临床试验统计分析计划中。
Clin Trials. 2022 Jun;19(3):285-291. doi: 10.1177/17407745221080463. Epub 2022 Mar 8.
6
Principles for Defining Estimands in Clinical Trials-A Proposal.《临床试验中定义估计量的原则——一项提案》
Pharm Stat. 2025 Jan-Feb;24(1):e2432. doi: 10.1002/pst.2432. Epub 2024 Aug 13.
7
Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic.ICH E9（R1）实施：在 COVID-19 大流行期间的几点体会。
Ther Innov Regul Sci. 2021 Sep;55(5):984-988. doi: 10.1007/s43441-021-00297-6. Epub 2021 May 13.
8
Estimands: discussion points from the PSI estimands and sensitivity expert group.估计量：来自PSI估计量与敏感性专家组的讨论要点
Pharm Stat. 2017 Jan;16(1):6-11. doi: 10.1002/pst.1745. Epub 2016 Mar 21.
9
Estimands for clinical endpoints in tuberculosis treatment randomized controlled trials: a retrospective application in a completed trial.结核病治疗随机对照试验中临床终点的估计值：在一项已完成试验中的回顾性应用
Trials. 2024 Mar 12;25(1):180. doi: 10.1186/s13063-024-07999-w.
10
Marking 2-Years of New Thinking in Clinical Trials: The Estimand Journey.标志着临床试验新思维的 2 年：效应量估计之旅。
Ther Innov Regul Sci. 2022 Jul;56(4):637-650. doi: 10.1007/s43441-022-00402-3. Epub 2022 Apr 24.
引用本文的文献
1
Applying the estimand framework to clinical pharmacology trials with a case study in bioequivalence.将估计量框架应用于临床药理学试验，并以生物等效性为例进行研究。
Br J Clin Pharmacol. 2025 Feb;91(2):310-324. doi: 10.1111/bcp.16347. Epub 2024 Nov 25.
本文引用的文献
1
Aligning Estimators With Estimands in Clinical Trials: Putting the ICH E9(R1) Guidelines Into Practice.临床试验中估算值与目标值的一致性：实践 ICH E9(R1) 指导原则。
Ther Innov Regul Sci. 2020 Mar;54(2):353-364. doi: 10.1007/s43441-019-00063-9. Epub 2020 Jan 6.
2
Beyond "Intent-to-treat" and "Per protocol": Improving assessment of treatment effects in clinical trials through the specification of an estimand.超越“意向性分析”和“符合方案分析”：通过明确估计量来改进临床试验中治疗效果的评估
Br J Clin Pharmacol. 2020 Jul;86(7):1235-1239. doi: 10.1111/bcp.14195. Epub 2020 Mar 27.
3
Assessing the ratio of means as a causal estimand in clinical endpoint bioequivalence studies in the presence of intercurrent events.在存在并发事件的情况下，评估均值比作为临床终点生物等效性研究中的因果估计量。
Stat Med. 2019 Nov 30;38(27):5214-5235. doi: 10.1002/sim.8367. Epub 2019 Oct 17.
4
Defining treatment effects: A regulatory perspective.定义治疗效果：监管视角。
Clin Trials. 2019 Aug;16(4):345-349. doi: 10.1177/1740774519830358. Epub 2019 Feb 14.
5
Treatment effect quantification for time-to-event endpoints-Estimands, analysis strategies, and beyond.事件发生时间终点的治疗效果量化——估计量、分析策略及其他。
Pharm Stat. 2019 Mar;18(2):145-165. doi: 10.1002/pst.1917. Epub 2018 Nov 26.
6
Estimation of causal effects in clinical endpoint bioequivalence studies in the presence of intercurrent events: noncompliance and missing data.在存在并发事件（不依从性和缺失数据）的情况下，临床终点生物等效性研究中因果效应的估计
J Biopharm Stat. 2019;29(1):151-173. doi: 10.1080/10543406.2018.1489408. Epub 2018 Jul 11.
7
Estimands: A More Strategic Approach to Study Design and Analysis.估计量：一种更具策略性的研究设计与分析方法。
Clin Pharmacol Ther. 2017 Dec;102(6):894-896. doi: 10.1002/cpt.872.
8
Residuals and outliers in replicate design crossover studies.重复设计交叉研究中的残差与异常值
J Biopharm Stat. 2010 Jul;20(4):835-49. doi: 10.1080/10543401003618876.
9
Noninferiority and equivalence designs: issues and implications for mental health research.非劣效性和等效性设计：对心理健康研究的问题及影响
J Trauma Stress. 2008 Oct;21(5):433-9. doi: 10.1002/jts.20367.
10
Why are pharmacokinetic data summarized by arithmetic means?为什么药代动力学数据要用算术平均值来汇总？
J Biopharm Stat. 2000 Feb;10(1):55-71. doi: 10.1081/BIP-100101013.
Zotero 插件